Our strategic planning of therapeutic areas for development of new and generic drugs, as well as cellular products is based on the in-depth analysis of the patient population needs in the Russian Federation for various medical products and treatments. Currently, we are pursuing research and development of therapies for the following diseases and pathological conditions.
Rare (orphan) congenital diseases. Congenital or acquired defects of coagulation factors.
Rare (orphan) congenital diseases
Treatment of rare diseases represents a significant socio-economic problem. The prevalence of these diseases is less than
Congenital or acquired defects of blood coagulation factors
Haemophilia is a disease characterized by the lack of the blood clotting factors; most commonly are being factor VIII or factor IX. It is among the most common congenital disorders of blood coagulation. Patients with haemophilia require frequent administration of the therapeutics, containing the missing factors. This demand in Russia has been covered by the generic medications Octofactor® (Factor VIII) and Innonafactor® (Factor IX), which were developed by our company. Following initial treatment, patients may develop a loss of feedback to coagulation factor inputs, which will require the use of alternative drugs that affect blood clotting. Such alternative medication is Coagyl®-VII (coagulation factor VII), that has also been developed by our company.
|GNR-001||Protein based Biosimilar||Registered|
|GNR-002||Protein based Biosimilar||Registered|
|GNR-003||Protein based Biosimilar||Registered|
|GNR-008||Protein based Biosimilar||Phase I clinical studies|
|GNR-021||Protein based Innovative||Preclinical trials in vivo|
|GNR-039||Protein based Biosimilar||Preclinical trials in vivo|